UroGen Pharma Ltd.
URGN
$18.44
-$0.35-1.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -153.49M | -164.64M | -154.97M | -138.43M | -126.87M |
| Total Depreciation and Amortization | 2.41M | 2.04M | 1.67M | 1.33M | 1.19M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.55M | 20.19M | 20.24M | 23.20M | 23.99M |
| Change in Net Operating Assets | -27.91M | 4.68M | 9.93M | 6.85M | 4.93M |
| Cash from Operations | -162.44M | -137.74M | -123.13M | -107.06M | -96.77M |
| Capital Expenditure | -289.00K | -387.00K | -396.00K | -339.00K | -295.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 61.85M | 94.85M | -43.29M | -59.76M | -20.32M |
| Cash from Investing | 61.56M | 94.46M | -43.69M | -60.09M | -20.61M |
| Total Debt Issued | -- | 0.00 | 24.49M | 24.49M | 24.49M |
| Total Debt Repaid | -1.86M | -- | -- | -- | -- |
| Issuance of Common Stock | 41.77M | 8.67M | 15.52M | 96.87M | 151.49M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 3.00K | 3.00K | 18.64M | 18.64M |
| Cash from Financing | 39.92M | 8.67M | 40.01M | 140.00M | 194.62M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -60.97M | -34.60M | -126.81M | -27.15M | 77.24M |